Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 19, 2015
Pharmacy Choice - News - Over-the-Counter Drugs - April 19, 2015

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 29     Next >>     Go To Page:

4/17/15 - Addressing Inadequate Information on Important Health Factors in Pharmacoepidemiology Studies Relying on Healthcare Databases; Public Workshop
The Food and Drug Administration is announcing a public workshop, cosponsored by FDA and the University of Maryland Center for Excellence in Regulatory Science and Innovation, entitled "Methodological Considerations to Address Unmeasured Information About Important Health Factors in Pharmacoepidemiology Studies that Rely on Electronic Healthcare...
4/17/15 - Half Of All Older Adults In US Now Taking Aspirin [Eurasia Review]
A national survey suggests that slightly more than half of the older adults in the United States are now taking a daily dose of aspirin, even though its use is not recommended by the Food and Drug Administration for most people who have not yet had a heart attack or stroke. The FDA has determined that in primary use to prevent a first heart attack
4/17/15 - OTC Markets Group Welcomes Newly Verified OTCQB Companies
Release date- 16042015- New York, NY- OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced the following companies are verified for trading on the OTCQB Venture Marketplace. Soligenix, Inc.- Soligenix is a late-stage biopharmaceutical company developing product candidates intended to address un
4/17/15 - SmallCap IR Issues Analyst Brief on That Marketing Solution: Proprietary Formula gives Company Competitive Advantage by IEW Research
That Marketing Solution, Inc. a development stage company, focuses on the production of products in the nutritional supplements industry. It acquired the rights to a proprietary formula for a blend of nutritional supplements called Low-T Vitamin Formula capsules that are intended to be a natural, non- FDA regulated, and over-the-counter supplemen
4/16/15 - Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast
To access the webcast, go to Actavis' Investor Relations Web site at http://ir.actavis.com. Actavis plc, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model Growth Pharma. Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous sy
4/16/15 - BSCG Certified Drug Free Program Addresses Unmet Supplement Adulteration Concerns, an Analysis of FDA Statistics Confirms
An analysis of the FDA's Tainted Supplements List reveals that 76% of the hidden drugs found in supplements are not banned in sport substances that only BSCG's pioneering program covers. The FDA's testing has shown that products may contain harmful compounds falling outside the scope of those banned by the World Anti-Doping Agency and elite and.
4/16/15 - Federal Register Table of Contents
Table of Contents Office of the Federal Register Agriculture Department SeeFederal Crop Insurance Corporation SeeForest Service SeeNational Agricultural Statistics Service Centers for Disease Control and Prevention NOTICES Guidance: NIOSH Current Intelligence Bulletin 67 Promoting Health and Preventing Disease and Injury through Workplace...
4/16/15 - OTC Markets Group Congratulates Corbus Pharmaceuticals Holdings on Uplisting to NASDAQ from OTCQB Venture Marketplace
OTC Markets Group Inc. congratulates Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, on its uplisting to the NASDAQ Capital Market. Corbus began trading on the OTCQB Venture Marketplace on October 24, 2014, at $3 per share. About OTC Markets Group Inc. OTC Markets Group Inc. operates Open, Transparent and Connec
4/16/15 - Perrigo Announces The Launch Of A Generic Version Of Kenalog Nasal Spray
Perrigo Company plc today announced that it has received final Federal Drug Administration approval for Triamcinolone Acetonide Topical Aerosol, the generic version of Sun Pharma's Kenalog nasal spray. Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This launch is another example of Perrigo's investment and commitment to making q
4/16/15 - Wellness Forever aims to treble store count, turnover [DNA : Daily News & Analysis (India)]
Mumbai: Wellness Forever, a Mumbai- based lifestyle pharmacy chain that received Rs 20 crore venture funding this month, has chalked out an ambitious plan to more than triple its turnover in the next three years. The company has presence in Maharashtra and one pharmacy inside a 220- bed hospital in Karnataka. While it plan to expand in Maharashtra,
4/15/15 - Axxess Pharma Provides Shareholder Update
Axxess Pharma Inc. a specialty pharmaceutical and nutritional supplements company through its wholly-owned subsidiary, AllStar Health Brands Inc., is pleased to provide a shareholder update for the first quarter ending 2015.. During the first quarter of 2015, Axxess Pharma continued their global expansion of their TapouT product line, while fulfi
4/15/15 - CASMED Receives FDA Approval for FORE-SIGHT ELITE; Provectus Opens Patient Enrollment of PV-10 for Melanoma
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 15, 2015.{ nfg} CAS Medical Systems, Inc., a leader in medical devices for non-invasive patient monitoring, announces receipt of an expanded label for its FORE-SIGHT ELITE oximeters from the FDA to include its new medium and small sensors for
4/15/15 - DS HEALTHCARE GROUP, INC. - 10-K -
Management's Discussion And Analysis Of Financial Condition And Results Of Operation. Information included or incorporated by reference in this filing may contain forward-looking statements. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be...
4/15/15 - Embera NeuroTherapeutics Secures $2 Million in A-2 Financing [Health & Beauty Close - Up]
Embera said that existing investors, angel groups, private individuals and HRA Pharma, based in Paris, participated in the round. HRA's Chief Executive Officer, Erin Gainer, Ph.D., will serve as a non-voting observer to Embera's Board of Directors. "We are excited that Embera is able to utilize metyrapone for its novel drug combination and are hap
4/15/15 - FDA Request Nomination for Industry Representatives, Participation from Industry Organizations on Public Advisory Committees
Dates: Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to FDA by May 15, 2015,. Concurrently, nomination materials for prospective candidates should be sent to FDA by May 15, 2015. The Food and Drug Administration is re
4/15/15 - Ipsen Biopharmaceuticals expands to Canada
-Ipsen Biopharmaceuticals Canada Inc., the Canadian affiliate of Ipsen announced today the official opening of its new Canadian headquarters in Mississauga, Ontario. The global biopharmaceutical company will join Ontario's growing biomedical cluster and deliver innovative specialty medicines based on Ipsen's expertise and leadership in peptide and.
4/15/15 - Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, is providing an update regarding their plan to market their over-the-counter pain reliever, Nyloxin through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma management has been working in Mumbai this
4/15/15 - Request for Nomination for Industry Representatives and Participation From Industry Organizations on Public Advisory Committees
SUMMARY: The Food and Drug Administration is requesting that any industry organizations interested in participating in the selection of nonvoting industry representatives to serve on its public advisory committees for the Center for Drug Evaluation and Research notify FDA in writing. FDA is also requesting nominations for nonvoting industry...
4/15/15 - VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents
VIVUS, Inc., a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical
4/14/15 - Durbin, Blumenthal 'Troubled' By FDA Inaction On Mislabeled Supplements
Senators Dick Durbin and Richard Blumenthal are calling on the Food and Drug Administration to investigate manufacturers of dietary supplements containing "acacia rigidula" which is often used on dietary supplement labels to mask the inclusion of BMPEA- a potentially dangerous synthetic stimulant- in their products. The Senators also criticized the
4/14/15 - Sunovion Pharmaceuticals Inc. to Present Data on Aptiom (eslicarbazepine acetate) at 67th American Academy of Neurology Annual Meeting
Sunovion Pharmaceuticals Inc. will present five research posters at the 67 th American Academy of Neurology Annual Meeting, including findings from two pooled Phase 3 studies evaluating the safety and efficacy of Aptiom as a potential monotherapy treatment of partial-onset seizures. It affects approximately two million people in the U.S., and th
4/13/15 - Actavis and Medicines360 Announce U.S. Availability of LILETTA? (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
DUBLIN and SAN FRANCISCO, April 13, 2015/ PRNewswire/ Actavis plc, a leading global pharmaceutical company and leader in women's health care, and Medicines360, a nonprofit women's health pharmaceutical company, announced today that LILETTA? 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years. "The ava
4/13/15 - Amneal Signs Deal to Acquire the Generic Business of Actavis Australia
By a News Reporter-Staff News Editor at Pharma Business Week Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc, announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis' in-country generic pharmaceuticals business for an agreed price, s
4/13/15 - ApexM Incontinence Device Cleared By FDA For Over-The-Counter Sale
The Food and Drug Administration has cleared ApexM for over-the-counter sale to treat stress, urge and mixed urinary incontinence in women. The ApexM, distributed by InControl Medical, LLC, provides muscle stimulation through a customizable probe to strengthen the pelvic floor and calms spasms of the bladder muscle, decreasing urgency.
4/13/15 - BUYINS.NET: CNC, WDR, VLO, DTE, GBL, TKR Expected To Be Up Before Next Earnings Releases
CENTENE CORPORATION, Waddell& Reed Financial Inc, Valero Energy Corp, DTE Energy Co, GAMCO Investors Inc, Timken Co are all expected to be Up Before their earnings are released. Symbol Company# of Reports Quarter Release Date. CNC CENTENE CORPORATION 12 Quarter Q1 04/28/2015.
Articles(s): 1 - 25 of 29     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415